Table 3.

Case series of COVID-19 patients (positive and presumed positive)

	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6
Age, sex	79 M	69 F	53 M	41 M	72 M	54 F
Race	Caucasian	Caucasian	African-American	Caucasian	Caucasian	Caucasian
Cancer	Renal cell Carcinoma	Pleomorphic sarcoma	Renal cell Carcinoma	Renal cell Carcinoma	NSCLC	Melanoma
ICI	Monotherapy	Combination	Monotherapy	Combination	Combination	Monotherapy
Last ICI dose	6/4/18	6/1/17	4/1/19	3/6/20	3/18/20	7/26/18
Cancer status	Stable	CR	Stable	PR	Stable	Stable
Arthritis status	Ongoing, stable	Ongoing, stable	Resolved	Ongoing, stable	Ongoing, improving	Resolved
Antirheumatic medications	None	NSAIDs	None	Prednisone 20 mg daily (for ICI-colitis)	Prednisone 7.5 mg daily	None
SARS-CoV-2 Symptoms	Cough, fever, headache, dizziness, weakness, diarrhea, change in taste	Cough, loss of smell and taste	Mental fatigue	Cough, shortness of breath	Loss of smell for 5 days	Asymptomatic
Hospitalized	No	No	No	Yes, for ICI-colitis; never intubated	No	No
Calendar month of illness	April 2020	March 2020	April 2020	March 2020	March 2020	Unknown
State of residence	New York	New York	New York	New York	New Jersey	New York
SARS-CoV-2 testing	Not tested	Not tested	Positive PCR	Positive PCR	Positive PCR	Positive Serology

CR, complete response; F, female; ICI, immune checkpoint inhibitor; M, male; NSAID, nonsteroidal anti-inflammatory drugs; NSCLC, non-small cell lung cancer; PR, partial response.